Infectious Vaccines Partnering Terms and Agreements, New Report Launched

The Infectious Vaccines Partnering Terms and Agreements provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2009, including financial terms where available, including over 500 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading infectious vaccines deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the big biotech companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since January 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious vaccines technologies and products.

Report scope

Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.

Infectious Vaccines Partnering Agreements includes:

• Trends in infectious vaccines dealmaking in the biopharma industry since 2009
• Analysis of infectious vaccines deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 500 infectious vaccines deal records
• The leading infectious vaccines deals by value since 2009
• Includes adjuvant deals and alliances since 2009

In Infectious Vaccines Partnering Agreements, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Infectious Vaccines Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

•  What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of infectious vaccines deal trends since 2009
• Access infectious vaccines deal headline, upfront, milestone and royalty data
• Analysis of the structure of infectious vaccines agreements with numerous real life case studies
• Comprehensive access to over 500 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
• Identify leading infectious vaccines deals by value since 2009
• Identify the most active infectious vaccines dealmakers since 2009
• Insight into the terms included in infectious vaccines agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 899 pages, “Infectious Vaccines Partnering Terms and Agreements” report covering the Executive Summary, Introduction, Trends in infectious vaccines dealmaking, Leading infectious vaccines deals, Big pharma infectious vaccines deals, Big biotech infectious vaccines deals, Infectious vaccines dealmaking directory. The report covered few companies are - A*STAR Agency for Science, Technology and Research,A*STAR Bioprocessing Technology Institute,A*STAR Singapore Immunology Network,Abbott Laboratories,ABEC,ABIVAX,Absynth Biologics,Academia Sinica,ACE BioSciences.

For more information see – http://mrr.cm/ZM9

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare